Authorized generics, released by brand-pharmaceutical companies as a way to deal with competition, can be as profitable as, if not more profitable than, brand-name drugs; an increasing reliance on fundraising appeals for healthcare needs can widen existing disparities and distort markets, particularly for prescription drugs; the Trump administration is considering releasing a healthcare plan in the fall.